Meta Analysis

Complete Revascularization with pVAD vs IABP

Analysis Showcases Potential for More Complete Revascularizations with Impella® Heart Pumps Compared to IABP during HRPCI

This page gives you an overview about the York data analysis - a pooled Individual Patient Data (IPD) comparison of pVAD and IABP in High-Risk PCI, presented by Vasileios Panoulas, MD, at EuroPCR 2023 (York I) and ESC 2023 (York II).

York I: Complete Revascularization with pVAD vs IABP

In Part 1 of the pooled data analysis led by the York Health Economics Consortium, Vasileios Panoulas, MD, and colleagues examined data from PROTECT II, PROTECT III, and RESTORE EF to explore the hypothesis that using a percutaneous LVAD, such as Impella® heart pumps, during high-risk percutaneous coronary intervention (HRPCI) helps achieve more complete revascularization compared to HRPCI supported with an intra-aortic balloon pump (IABP).

York II: Acute Coronary Syndromes and High-Risk PCI: State of the Art

In Part 2 of the York data analysis, Dr. Panoulas and colleagues looked at data from PROTECT II and RESTORE EF to investigate the relationship between completeness of revascularization, NYHA heart failure class, and 90-day LVEF in patients undergoing HRPCI with either Impella or IABP. 

York Data Analysis About Complete Revascularization With pVAD vs IABP: York I vs York II - A Comparison York Data Analysis About Complete Revascularization With pVAD vs IABP: York I vs York II - A Comparison

York Data Analysis About Complete Revascularization With pVAD vs IABP: York I vs York II - A Comparison

Learn more about the differences and key points between part I and part II of the York data set.

Complete Revascularization with pVAD vs IABP

Complete Revascularization with pVAD vs IABP

At EuroPCR 2023, Vasileios Panoulas, MD, presented results of a third-party analysis comparing complete revascularization (CR) rates in high-risk PCI patients who received Impella support compared to intra-aortic ballooon pump (IABP) support.

NYHA Class Improvement

Acute Coronary Syndromes and High-Risk PCI: State of the Art

Vasileios Panoulas, MD, and colleagues pooled individual patient data from the PROTECT II randomized controlled trial and the RESTORE EF study and found that baseline SYNTAX score, residual SYNTAX score (rSS), and LVEF at baseline were significant predictors of NYHA class at 90 days after high-risk PCI.

 

A “Treasure Trove” of Complete Revascularization Data

Vasileios Panoulas, MD, discusses an individual patient data pooling from the PROTECT II RCT, PROTECT III, and RESTORE EF trials released at EuroPCR 2023.

 

ESC 2023: Predictors of 90-day Outcomes from York Analysis

Vasileios Panoulas, MD, discusses a pooled analysis of factors predicting outcomes at 90 days in high-risk PCI patients.

Learn More About Clinical Evidence Related to Impella

 

Clinical Trial Update with Chuck Simonton, MD

Chuck Simonton, MD, provides an update on clinical trials including PROTECT III, RESTORE EF, and PROTECT IV RCT.

 

RESTORE EF Case Study: Contemporary Practices for Impella®-Supported Complete Revascularization

Jason Wollmuth, MD, describes best practice techniques for Impella-supported complete revascularization in a RESTORE EF case.

 

Dr. Jonathan Hill: Influential Trials in High-risk PCI–TCT 2022

At TCT 2022, Jonathan Hill, MD, presents the influential high-risk PCI trials shaping the future of ischemic heart failure therapy.

NPS-3763

This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].